Search
Contineum Therapeutics Inc
CTNMAdd to Watchlist
9.860USD
+0.080+0.82%
Close 11-13 16:00（ET）
370.93MMarket Cap
LossP/E TTM
Contineum Therapeutics Inc (CTNM) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Contineum Therapeutics Inc in the past month.
Buy
3 Strong Buy
3 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
22.143USD+135.81%
CTNM Analyst Recommendation Trends
In the current month, CTNM has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CTNM average Analyst price target in the last month is 22.143.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
4
4
4
4
4
4
3
3
3
2
2
2
2
2
2
2
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
7
7
7
7
7
CTNM Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CTNM EPS is projected to reach -0.461 in FY2026Q4, following reported EPS of -0.487 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.53
-0.45
-0.45
-0.46
-0.50
Actual
-0.39
-0.40
-0.49
--
--
Surprise
+27.15%
+10.45%
-7.33%
--
--
FAQs
What is Contineum Therapeutics Inc's price target?
Analysts forecast that Contineum Therapeutics Inc's price target is USD 21.43, with the highest forecast at USD 30.00 and the lowest forecast at USD 14.00.
How have Contineum Therapeutics IncCTNM's recent earnings per share performed?
The market expectation was USD -0.49, while Contineum Therapeutics IncCTNM's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.46.
What is the analyst rating for Contineum Therapeutics Inc?
Based on the ratings of Contineum Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.